Structural and Chemical Modification of Cellular Wood Composite for Enhanced Strength, Fire, and Biological Resistance. [PDF]
Koo MS +4 more
europepmc +1 more source
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad +35 more
wiley +1 more source
Review of research progress in immobilization and chemical modification of microbial enzymes and their application. [PDF]
Wahab WAA.
europepmc +1 more source
Stradivari's Varnish Revisited: Feature Improvements Using Chemical Modification. [PDF]
Weththimuni ML +6 more
europepmc +1 more source
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Challenges of Aufheben to Promote Druglikeness: Chemical Modification Strategies to Improve Aqueous Solubility and Permeability. [PDF]
Ishikawa M, Tomoshige S, Sato S.
europepmc +1 more source
ATF4‐mediated stress response as a therapeutic vulnerability in chordoma
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone +11 more
wiley +1 more source
An siRMSD parameter of structural distortion induced by chemical modification is predictive of the off-target effect of siRNA. [PDF]
An S +5 more
europepmc +1 more source
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
Design and systematic evaluation of novel chemical modification patterns enable the identification of a potent siRNA targeting <i>PCSK9</i>. [PDF]
Huang ZA +7 more
europepmc +1 more source

